Expression of CCL5 (RANTES) and CCR5 in prostate cancer

Prostate

Volumn 66, Issue 2, 2006, Pages 124-134

  Vaday, Gayle G ^a,b   Peehl, Donna M ^c   Kadam, Pournima A ^a   Lawrence, Diana M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokine; Inflammation; Prostate cancer

Indexed keywords

CELL PROTEIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MESSENGER RNA; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RANTES; RECOMBINANT CYTOKINE; RECOMBINANT RANTES; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; BREAST TUMOR; CANCER GROWTH; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; AMIDES; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CHEMOKINES, CC; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 31944433180     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20306     Document Type: Article

References (50)

1. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001;357:539-545.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
3. Nelson WG, DeMarzo A, Isaacs WB. Prostate cancer. New Engl J Med 2003;349:366-381.
4. Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: A case-control study in southeast China. Int J Cancer 2004;108:130-135.
5. Chen L, Stacewicz-Sapuntazakis M, Duncan C, Sharifi R, Ghosh L, van Breemen R, Ashton D, Bowen PE. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001; 93:1872-1879.
6. Nelson WG, De Marzo A, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004;172:S6-S12.
7. Lucia MS, Torkko KC. Inflammation as a target for prostate cancer chemoprevention: Pathological and laboratory rationale. J Urol 2004;171:S30-S35.
8. DeMarzo A, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG. Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004; 91:459-477.
9. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77:511-515.
10. Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004;10:7727-7737.
11. Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urology 2004;171:S59-S63.
12. De Marzo A, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG. Human prostate cancer precursors and pathobiology. Urology 2003;62(Suppl 5A):55-62.
13. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62:1832-1837.
14. Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Streiter RM. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999;154:1503-1512.
15. Reiland J, Furcht LT, McCarthy JB. CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate 1999;41:78-88.
16. Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C, Jimenez-Baranda S, Garzon A, Lacalle R, Harshman K, Ruiz A, Martinez-A C. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003;198:1381-1389.
17. Inoue K, Slaton JW, Eve BY, Kim SJ, Perotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000;6:2104-2119.
18. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (Pea) in vivo. J Cell Biochem 2003;89:462-473.
19. Vaday GG, Hua SB, Peehl DM, Pauling MH, Lin YH, Zhu L, Lawrence DM, Foda HD, Zucker S. CXCR4 and CXCL12 (SDF-1) in prostate cancer: Inhibitory effects of human single chain Fv antibodies. Clin Cancer Res 2004;10:5630-5639.
20. Mule J, Custer M, Averbook B, Yang J, Weber J, Goeddel D, Rosenberg S, Schall T. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations. Hum Gene Ther 1996;7:1545-1553.
21. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I, Ben-Baruch A. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999;59:4681-4687.
22. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7:285-289.
23. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R. Molecular profiling of inflammatory breast cancer: Identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004;10:6789-6795.
24. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AEI, Balkwill F. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003;63:8360-8365.
25. Mrowietz U, Schwenck U, Maune S, Bartels J, Kupper M, Fichtner I, Schroder J-M, Schadendorf D. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer 1999;79:1025-1031.
26. Fischer M, Juremalm M, Olsson N, Backlin C, Sundstrom C, Nilsson K, Enblad G, Nilsson G. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003;107:197-201.
27. Mori N, Krensky AM, Ohshima K, Tomita M, Matsuda T, Ohta T, Yamada Y, Tomonaga M, Ikeda S, Yamamota N. Elevated expression of CCL5/RANTES in adult T-cell leukemia cells: Possible transactivation of the CCL5 gene by human T-cell leukemia virus type I tax. Int J Cancer 2004;111:548-557.
28. Negus RP, Stamp GW, Hadley J, Balkwill F. Quantitative assessment of the leukocyte infiltrate in ovarian cancers and its relationship to the expression of C-C chemokines. Am J Pathol 1997;150:1723-1734.
29. Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urology 2004;171:2171-2175.
30. Konig JE, Senge T, Allhoff EP, Konig W. Analysis of inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004;58:121-129.
31. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-5703.
32. Peehl DM. Human prostatic epithelial cells. In: Freshney RI, Freshney MG, editors. Culture of epithelial cells. 2nd ed. New York: Wiley-Liss; 2002. pp 171-194.
33. Wang J, Xi L, Hunt JL, Gooding W, Whiteside TL, Chen Z, Godfrey TE, Ferris RL. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res 2004; 64:1861-1866.
34. Manes S, Mira E, Gomez-Mouton C, Lacalle R, Keller P, Labrador JP, Martinez-A C. Membrane raft microdomains mediate front-rear polarity in migrating cells. EMBO J 1999;18:6211-6220.
35. Prest S, Rees R, Murdoch C, Marshall J, Cooper P, Bibby M, Li G, Ali S. Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: Subpopulations of tumour cells display positive and negative chemotaxis and differential in vivo growth potentials. Clin Exp Metastasis 1999;17:389-396.
36. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A. The CC chemokine RANTES in breast carcinoma progression: Regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002;62:1093-1102.
37. Youngs SJ, Ali SA, Taub DD, Rees RC. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 1997;71:257-266.
38. Melani C, Pupa SM, Stoppacciaro A, Menard S, Colnaghi MI, Parmiani G, Colombo MP. An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different Chemokines. Int J Cancer 1995;62:572-578.
39. Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 2002;8:3803-3812.
40. De Marzo A, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-1992.
41. Kutubuddin M, Federoff HJ, Challita-Eid PM, Halterman M, Day B, Atkinson M, Planelles V, Rosenblatt JD. Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 1999;93:643-654.
42. Adler EP, Lemken CA, Katchen NS, Kurt RA. A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett 2003; 90:187-194.
43. Kurt RA, Baher A, Wisner KP, Tackitt S, Urba WJ. Chemokine receptor desensitization in tumor-bearing mice. Cell Immunol 2001;207:81-88.
44. Uekusa Y, Yu WG, Mukai T, Gao P, Yamaguchi N, Murai M, Matsushima K, Obika S, Imanishi T, Higashibata Y, Nomura S, Kitamura Y, Fujiwara H, Hamaoka T. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment of tumor-bearing mice. Cancer Res 2002;62:3751-3758.
45. Appay V, Rowland-Jones SL. RANTES: A versatile and controversial chemokine. Trends Immunol 2001;22:83-87.
46. Bohm SK, Grady EF, Bunnett NW. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem J 1997;322:1-18.
47. Signoret N, Oldridge J, Pelchen-Matthews A, Klasse PJ, Tran T, Brass LF, Rosenkilde MM, Schwartz TW, Holmes W, Dallas W, Luther MA, Wells TN, Hoxie JA, Marsh M. Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol 1997;139:651-664.
48. Franitza S, Kollet O, Brill A, Vaday GG, Petit I, Lapidot T, Alon R, Lider O. TGF-beta1 enhances SDF-1alpha-induced chemotaxis and homing of naive T cells by up-regulating CXCR4 expression and downstream cytoskeletal effector molecules. Eur J Immunol 2002;32:193-202.
49. Rubin JB, Kung AL, Klein RS, Chan JA, Sun YP, Schmidt K, Kieran MW, Luster AD, Segal RA. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003;100:13513-13518.
50. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004; 64:4302-4308.